Alnylam Pharmace. buy StockNews.com
Start price
13.04.24
/
50%
€140.85
Target price
13.04.25
-
Performance (%)
45.76%
End price
14.04.25
€205.30
Summary
This prediction ended on 14.04.25 with a price of €205.30. With a performance of 45.76% the BUY prediction by StockNews_com was a big success. StockNews_com has a follow-up prediction for Alnylam Pharmace. where he still thinks Alnylam Pharmace. is a Buy. StockNews_com has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Alnylam Pharmace. | 1.240% | 1.240% | 47.084% |
| iShares Core DAX® | 2.659% | 4.844% | 23.110% |
| iShares Nasdaq 100 | 0.916% | -0.554% | 6.985% |
| iShares Nikkei 225® | 2.426% | 1.598% | 15.780% |
| iShares S&P 500 | 1.230% | 1.039% | 4.695% |
Comments by StockNews_com for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Ratings data for ALNY provided by MarketBeat
In the thread Trading Alnylam Pharmace.
Die von StockNews_com gewählte maximale Laufzeit wurde überschritten